Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline Review, H2 2017’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)

The report reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ankylosing Spondylitis (Bekhterev's Disease) therapeutics and enlists all their major and minor projects

The report assesses Ankylosing Spondylitis (Bekhterev's Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amgen Inc

Biocad

Biocon Ltd

Bionovis SA

Celgene Corp

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Galapagos NV

Genor BioPharma Co Ltd

Immunwork Inc

Innovent Biologics Inc

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Novartis AG

Oncobiologics Inc

Protalix BioTherapeutics Inc

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Shanghai Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

UCB SA

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Ankylosing Spondylitis (Bekhterev's Disease) - Overview 10

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Products under Development by Companies 15

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 26

AbbVie Inc 26

Adello Biologics LLC 26

Allergan Plc 27

Alteogen Inc 27

Amgen Inc 27

Biocad 28

Biocon Ltd 28

Bionovis SA 29

Celgene Corp 29

Coherus BioSciences Inc 30

Fresenius SE & Co KGaA 30

Galapagos NV 31

Genor BioPharma Co Ltd 31

Immunwork Inc 32

Innovent Biologics Inc 32

Mycenax Biotech Inc 32

Nichi-Iko Pharmaceutical Co Ltd 33

Novartis AG 34

Oncobiologics Inc 34

Protalix BioTherapeutics Inc 35

Reliance Life Sciences Pvt Ltd 35

Sandoz International GmbH 36

Shanghai Pharmaceutical Co Ltd 36

Sun Pharma Advanced Research Company Ltd 36

UCB SA 37

Xbrane Biopharma AB 37

Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles 39

adalimumab biosimilar - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

adalimumab biosimilar - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

adalimumab biosimilar - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

adalimumab biosimilar - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

adalimumab biosimilar - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

adalimumab biosimilar - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

adalimumab biosimilar - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

adalimumab biosimilar - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

adalimumab biosimilar - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

adalimumab biosimilar - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

adalimumab biosimilar - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

adalimumab biosimilar - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

adalimumab biosimilar - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

adalimumab biosimilar - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

apremilast - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

BCD-085 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

bimekizumab - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

certolizumab pegol biosimilar - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

DNX-114 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

DNX-514 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

etanercept biosimilar - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

etanercept biosimilar - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

etanercept biosimilar - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

etanercept biosimilar - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

etanercept biosimilar - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

etanercept biosimilar - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

etanercept biosimilar - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

filgotinib - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

golimumab biosimilar - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

golimumab biosimilar - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

HEISCO-III-002 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

infliximab biosimilar - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

infliximab biosimilar - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

infliximab biosimilar - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

infliximab biosimilar - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

infliximab biosimilar - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

infliximab biosimilar - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

infliximab biosimilar - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

risankizumab - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

secukinumab - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

TE-2122 - Drug Profile 131

Product Description 131

Mechanism Of Action 131

R&D Progress 131

TE-2158 - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

thalidomide - Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

tildrakizumab - Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

upadacitinib tartrate - Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

VTP-43742 - Drug Profile 144

Product Description 144

Mechanism Of Action 144

R&D Progress 144

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 147

Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 149

Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 150

Featured News & Press Releases 150

Nov 06, 2017: Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years 150

Oct 30, 2017: Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA 150

Jun 15, 2017: Novartis Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years 151

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 153

Nov 14, 2016: Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain 153

Oct 31, 2016: Novartis Wins Prestigious Prix Galien Foundation Award, Cosentyx as Best Biotechnology Product 154

Sep 28, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx (Secukinumab) 155

Sep 12, 2016: Innovent IBI303 to Initiate Pivotal Clinical Comparability studies with Adalimumab 155

Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis 156

Aug 04, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx 156

Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 157

Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada 158

Jan 20, 2016: Diplomat Announces COSENTYX Availability for the Treatment of Two New Indications 158

Jan 15, 2016: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US 159

Dec 23, 2015: Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients 160

Appendix 162

Methodology 162

Coverage 162

Secondary Research 162

Primary Research 162

Expert Panel Validation 162

Contact Us 162

Disclaimer 163

List of Tables

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Number of Products by Stage and Target, H2 2017 19

Number of Products by Stage and Mechanism of Action, H2 2017 21

Number of Products by Stage and Route of Administration, H2 2017 23

Number of Products by Stage and Molecule Type, H2 2017 25

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by AbbVie Inc, H2 2017 26

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Adello Biologics LLC, H2 2017 26

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Allergan Plc, H2 2017 27

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Alteogen Inc, H2 2017 27

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Amgen Inc, H2 2017 28

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocad, H2 2017 28

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocon Ltd, H2 2017 29

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bionovis SA, H2 2017 29

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Celgene Corp, H2 2017 30

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Coherus BioSciences Inc, H2 2017 30

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Fresenius SE & Co KGaA, H2 2017 31

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Galapagos NV, H2 2017 31

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Genor BioPharma Co Ltd, H2 2017 32

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Immunwork Inc, H2 2017 32

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Innovent Biologics Inc, H2 2017 32

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Mycenax Biotech Inc, H2 2017 33

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017 33

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Novartis AG, H2 2017 34

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Oncobiologics Inc, H2 2017 34

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Protalix BioTherapeutics Inc, H2 2017 35

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 35

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sandoz International GmbH, H2 2017 36

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017 36

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 37

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by UCB SA, H2 2017 37

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Xbrane Biopharma AB, H2 2017 38

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, H2 2017 147

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, H2 2017 (Contd..1), H2 2017 148

Ankylosing Spondylitis (Bekhterev's Disease) – Discontinued Products, H2 2017 149

List of Figures

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products by Top 10 Targets, H2 2017 18

Number of Products by Stage and Top 10 Targets, H2 2017 18

Number of Products by Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Routes of Administration, H2 2017 22

Number of Products by Stage and Routes of Administration, H2 2017 22

Number of Products by Molecule Types, H2 2017 24

Number of Products by Stage and Molecule Types, H2 2017 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports